Stock comparison
Moderna, Inc. is 9.2x more valuable than BIO-TECHNE Corp by market capitalization ($105.32 B vs $11.43 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 9.2x more valuable than BIO-TECHNE Corp by market capitalization ($105.32 B vs $11.43 B).
Market value leader
MRNA
Moderna, Inc. is 9.2x more valuable than BIO-TECHNE Corp by market capitalization ($105.32 B vs $11.43 B).
Revenue leader
MRNA
TECH: $1.22B vs MRNA: $1.94B.
Profit leader
TECH
TECH: $73.40M vs MRNA: -$2.82B.
Margin leader
TECH
TECH: 6.0% vs MRNA: -145.2% net margin.
| Metric | TECH | MRNA |
|---|---|---|
| Market cap | $11.43 B | $105.32 B |
| US-listed rank | #861 | #145 |
| Revenue (latest FY) | $1.22B | $1.94B |
| Net income (latest FY) | $73.40M | -$2.82B |
| Net margin | 6.0% | -145.2% |
| P/E (trailing FY) | 155.7x | - |
| SEC filings | 1,229 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 9.2x more valuable than BIO-TECHNE Corp by market capitalization ($105.32 B vs $11.43 B).
In their latest fiscal years, BIO-TECHNE Corp reported $1.22B in revenue while Moderna, Inc. reported $1.94B.
Full pages: BIO-TECHNE Corp and Moderna, Inc., or browse the full rankings.